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ABSTRACT

Characterization of Calmodulin
From Cg Astrocytoma Cells and Rat Cerebrum

Jay A1an Gates
1986

Calmodulin

(CaM)

regulates

many

processes

associated

proliferation and CaM antagonists can inhibit cell growth.
or

not

exploitable

malignant

tissue,

pharmacological
we

purified

with

To determine whether

differences exist between

CaM

by

preparative

cellular

a normal

polyacrylamide

and
gel

electrophoresis (PAGE) from rat cerebrum and the Cg malignant astrocytoma cell
line and compared the biochemical
preparations.

and pharmacological properties of the two

The concentration of biologically active CaM in the heated,

acidified supernatants was similar, being 37 + 14 ng/mg protein in cerebrum
compared to 26 + 7 ng/mg protein in Cg cells.

The proteins eluted similarly

from a preparative PAGE column, co-migrated in denaturing SDS-PAGE gels, and
showed

similar

shifts

of

mobility

when

calcium

was

present

during

electrophoresis.
We tested the sensitivity of the two preparations of CaM to several classes
of antagonists.

No significant difference in the sensitivities to any of the

classes of drugs was demonstrable when assayed by the inhibition of a CaMsensitive cyclic nucleotide phosphodiesterase.

We conclude that at least in

one malignant cell line, the pharmacological properties of CaM are similar to
those of normal tissue.

I
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INTRODUCTION
Calmodulin and normal cellular proliferation
Calmodulin (CaM*) is a heat and acid-stable, low molecular weight protein
which was first described independently by Cheung (1) and Kakiuchi
activator of cyclic AMP phosphodiesterase.

(2) as an

Teo and Wang showed that the same

protein, in a purified form, bound calcium at multiple sites; they suggested
that it was the complex of activator protein and calcium which was responsible
for increased cyclic AMP phosphodiesterase activity (3).

CaM, as the major

intracellular calciuim receptor, has since been shown to be involved in many
processes that are necessary for normal cellular proliferation (for reviews
see 4-7).

For example, CaM changes in concentration as cells enter and traverse

the cell cycle.

Chafouleas et al demonstrated that CaM levels are elevated

two-fold at late
cells (8).

and/or early S phases during the growth cycle of CHO-K^

Sasaki and Hidaka showed that CaM concentrations increased after

CH0-K;[ cells entered the S phase and reached a maximum level at the late G£
or early M phase (9).
partial

It has been shown by MacManus and coworkers that fol lowing

hepatectomy, CaM increases in regenerating hepatocytes, an increase

which coincides with the time when calcium is required for the initiation of
DNA synthesis

(10).

CaM is also known to stimulate the polymerization and

depolymerization of microtubules.

Welsh et al used indirect immunofluorescence

techniques to demonstrate the localization of CaM to the spindle of mitotic

*The abbreviations used are: CaM, calmodulin; EGTA, ethylene glycol

bis (13-

aminoethyl ether)-N,N,N',N'-tetraacetic acid; FBS, fetal bovine serum; PMSF,
phenylmethylsulfonylf1uoride;

TEMED,

N,N,N1,N'-tetramethylethylenediamine;

PAGE,polyacrylamide gel electrophoresis; PDE, phosphodiesterase; SDS, sodium
dodecylsulfate.

W-7, N-(6-aminohexyl)-5-chloro-l-napthalenesulfonamide

.

2

cells (11).

Marcum and coworkers expanded on Welsh's work and showed that

during anaphase CaM was restricted to the chromosome-to-pole region of the
mitotic apparatus and that CaM was involved in the control of calcium dependent
inhibition and reversal of microtubule assembly jjn vitro (12).
also showed that while both CaM and tubulin

Welsh et al

are components of the mitotic

apparatus, their localizations throughout mitosis are distinctly different and
specific (13).
was

almost

Job and coworkers showed that a subpopulation of microtubules

totally

resistant

disassembled rapidly
concentrations (14).

in

to

the

effect

the presence of

of

both

at

calcium

or

apparently

CaM

alone

but

physiological

It is also known that CaM modulates enzymes necessary

for generation of cellular energy.

Anderson and Cormier showed that CaM from

the pea plant, Pi sum satavum c., modulates NAD kinase activity in a calciumdependent fashion (15).

CaM also modulates enzymes necessary for control of

cyclic nucleotide metabolism (1,16).
the

several

molecular

forms

of

Uzunov and Weiss demonstrated that of
cyclic

adenosine

3',5'-monophosphate

phosphodiesterase, only one was really susceptible to activation by CaM (17).
It has also been shown that CaM is capable of stimulating adenylate cyclase
activity (18,19).
Calmodulin in states of abnormal cellular proliferation
In states of abnormal cellular proliferation, as occurs in transformed
or malignant cells, control of calcium and CaM mediated events is altered (for
reviews

see

7,20-22).

Watterson

and

coworkers

found

that

CaM

comprised

approximately 1.3% of the soluble protein in homogenates of chicken embryo
fibroblasts infected and transformed by Rous sarcoma virus as compared to 0.3%
of the soluble protein in homogenates of normal fibroblasts (23).

Balk et al

have observed that transformed chick embryo fibroblasts have the ability to
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grow in calcium concentrations that are 10-fold lower than that required for
proliferation

of

radioimmunoassay
intracellular
transformed
hepatoma

normal

cells

(24).

Chafouleas

techniques

to

demonstrate

concentration

of

CaM

by oncogenic

tissue

lines

viruses

to

in

adult

By

liver

coworkers
increase

tissue

comparing

demonstrated that both CaM activity and total
neoplastic tissue (20).

two-fold

mammalian

(25).

normal

a

and

tissue,

in

culture

fast-growing
Criss

and

used
the
cells
Morris

Kakiuchi

calcium are increased in the

Wei et al have demonstrated, in slowly and rapidly

growing hepatomas, that increased CaM levels are directly proportional to tumor
growth rate (26).

It should be noted that Veigl and coworkers believe that

the variation in CaM content, observed between normal and transformed cells,
is complex and may in part depend on culture conditions; they suggest that the
apparent

inability of transformed

cells

to

down-regulate CaM

levels

is

a

function of differing abilities of normal and transformed cultures to respond
to cell-to-cell contact and/or transmediated cellular regulation signals (27).
The inhibition of abnormal cellular proliferation by CaM antagonists
Drugs that share the property of CaM antagonism are known to inhibit the
growth of many malignant cell lines (for review see 7).
et al

used the macrophage-like cell

line

J774

For example. Speaker

(established from a murine

reticulum cell sarcoma) to demonstrate the inhibition of growth and Fc-mediated
phagocytosis by the CaM antagonist trif1uoperazine (28).

In several studies

Hait and coworkers have shown that the CaM antagonists calmidazoliurn, melittin,
pimozide,

trifluoperazine,

and

chlorpromazine

inhibit

the

growth

and/or

clonogenicity of human and murine leukemic cells, and rat astrocytoma cells;
they have demonstrated that the potency of these drugs, as inhibitors of cell
growth, correlates directly with their activity as inhibitors of CaM (29-32).
Ito and Hidaka were able to demonstrate a significant anti-tumor effect when

they gave intraperitoneal injections of W-7, a calmodulin antagonist, to mice
implanted with solid Sarcoma-180 (33). Wei et al, using a soft agar clonogenic
assay, showed that trif1uoperazine and W-7 inhibited colony formation in the
human breast cancer cell line, MDA-MB-231 (34). MacNeil and coworkers concluded
that W-7 and prochlorperazine markedly inhibited DNA synthesis in B-16 melenoma
cells, and that the inhibitory effect of these CaM antagonists was reversed
by the presence of exogenous CaM (35).
CaM antagonists have also been shown to, at least partially, overcome
tumor cell resistance to certain chemotherapeutic agents.

For example, Tsuruo

et al have shown that certain CaM inhibitors, as well as calcium antagonists,
enhance the cytotoxic effects of vincristine and adriamycin in resistant P388
leukemic cells; this effect was attributed to enhanced intracellular levels
of vincristine and adriamycin, possibly due to inhibition of their outward
transport (36).

In a similar system, Ganapathi

and Grabowski

demonstrated

that trifluoperazine markedly enhanced cellular retention of, and sensitivity
to,

adriamycin

only

in

adriamycin-resistant

tumor

sublines

and

not

in

adriamycin-sensitive lines (37).
The existence of novel calmodulins
Recently, novel CaMs have been identified in several organisms including
Tetrahymena (38), Dictyosteliurn (39), and trypanosomes (40).
forms of the molecule differ structurally, functionally,
(41) from mammalian CaM.

These altered

and antigenically

For example, Yazawa and coworkers have described a

Tetrahymena CaM (differing from bovine brain CaM by 11 amino acid substitutions
and one deletion)

which

guanylate cyclase (38).

is

unique

in

its

ability to activate Tetrahymena

Ruben et al have isolated CaM from the trypanosome

parasite which is structurally and functionally distinct from that of host
tissue (40).

Marshak and coworkers demonstrated that Dictyosteliurn CaM was
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able to activate bovine brain cyclic nucleotide PDE as effectively as bovine
brain CaM;

however,

it could activate pea NAD kinase 5 times greater than

bovine brain CaM (39).

One of the key distinctions between Dictyostelium CaM

and bovine brain CaM is that Dictyostel i um CaM's lysine 115 is not trimethyl ated
and has been shown by Gregori et al to be a ubiquitin conjugation site (42);
these

investigators

have

demonstrated

that

mammalian

CaM,

which

contains

trimethylysine at the 115 position, does not form conjugates with ubiquitin
and thus, unlike dictyostelium CaM, is "protected" from ubiquitin-dependent,
protein degradation pathways.
Furthermore,

recent evidence suggests that different CaMs might exist

within the same organism.

Putkey and coworkers have isolated a distinct "CaM-

like" gene from chicken which results in a protein product similar to normal
chicken CaM, yet it contains 16 amino acid substitutions and activates rat
brain PDE with slightly different kinetics (43). Siegel and Wright report the
isolation of a "CaM-isotype" from beef testes which activates cyclic nucleotide
PDE equally as well as does "standard" beef testes CaM, yet which stimulates
a distinctly different protein methylation pattern

in

rat

liver

cytosolic

fractions (44).
The potential use of calmodulin antagonists as antineoplastic agents
Based on the above findings, and the remarkable genetic diversity of tumor
cells, we postulated that alterations in CaM during malignant transformation
could occur which might help explain the ability of tumor cells to thrive in
lower concentration of calcium compared to their normal counterparts (45) or
which might provide a target for selective inhibition by drugs (7).
of

the

mounting

antineoplastic

interest

agents

chemotherapeutic

alone

agents

in

the

potential

(7,29-34),

(36,37),

it

use

of

CaM

Because

antagonists

as

or to modulate resistance to known

would

be

important

to

know

whether

6

exploitable pharmacological

differences

exist

between

the molecule from

a

malignant cell and that of its normal counterpart.
Isolation of CaM by preparative polyacrylamide gel electrophoresis
We also tested the feasibility of preparing CaM by preparative-PAGE, a
simple, rapid technique for the isolation and purification of other proteins
(17).

Therefore, we have established conditions for purifying CaM from normal

and malignant cells by preparative-PAGE and report the application of these
methods to the C5 astrocytoma cell line and normal cerebrum.

7

MATERIALS AND METHODS
Cell culturing techniques
Cg rat astrocytoma cells were obtained from the American Type Culture
Collection

(Rockville, MD).

This glial

cell

tumor of rats was originally

induced by intravenous injection of N-nitrosomethylurea.

Cells were cultured

at 37°C in a 5% atmosphere of CO2 in plastic flasks in monolayers in Dulbecco's
modification of Eagle's medium supplemented with 10% FBS.

Cells were passed

twice weekly and were shown to be free of contamination by routinely assaying
for mycoplasm, bacteria and fungi.
Isolation and Purification of CaM from C^ astrocytoma cells and rat cerebrum
Cg astrocytoma cells, at a concentration of approximately 100,000 cells
per ml, were seeded on to 250 x 250 x

20 mm, plastic plates

Denmark)

Dulbecco's modification of Eagle's

and were

incubated at 37°C

in

(Nunc Corp.,

medium with 10% FBS in a 5% atmosphere of CO2 for 3-4 days until confluent
(doubling time approximately 18 hrs).

Cells were harvested with a rubber

spatula, pooled, and centrifuged at 450 x g for 20 minutes at 2°C.
discarded and cells were washed with cold, fresh medium.

Medium was

Cells were homogenized

in 1.5 volumes of phosphate buffer containing 90 mM Na^PO^ 20 mM Na2HP04,
0.1

mM EGTA, 0.5 mM PMSF,

(Tekmar, Cincinnati, OH).

(pH 6.0) for twenty seconds with

a Tissumizer^

The homogenate was then sonicated 10 pulses at 50

watts, (TekmarR, Cincinnati, OH) in the presence of additional PMSF (0.5 mM).
All procedures were carried out on ice.
Female Sprague-Dawley rats (Charles River, Kingston) were maintained on
normal rat chow and distilled water.

Rats weighing approximately 200 grams

were decapitated with a Harvard Dispatcher.
rinsed with distilled water,

The cerebrum was removed, weighed,

and patted dry.

Tissue was suspended

in 1.5

8

volumes of the phosphate buffer (pH 6.0) and was homogenized and sonicated as
above.
The sonicated material was then placed in a boiling water bath for five
minutes.

The coagulated proteins were removed by centrifugation at 3400 x g

for 20 minutes at 2°C (Model J-6B centrifuge, Beckman, Palo Alto, CA).

The

supernatant was readjusted to a pH of 6.0, placed in a boiling water bath for
five minutes then recentrifuged.

A portion of the supernatant was dialyzed

overnight (against 50 mM Tris, 0.2 mM CaCl2, pH 7.4) for determination of CaM
activity

and

concentration

of

protein.

concentrated by ultrafiltration
Amicon, Danvers, MA).

The

remaining

(YM5 membrane, mol.

wt.

supernatant

was

cut off of 5,000,

Sucrose was added to the concentrate to yield a final

concentration of 0.32M and was applied to a 345 mm x 25 mm gel

filtration

column (G-75 Super Fine Sephadex, Pharmacia, Piscattaway, NJ) pre-equi1ibrated
with el ution buffer containing 5mM TRIS-base, 0.1 mM EGTA, 1 mM mercaptoethanol,
(pH 7.4).

1.5 ml fractions were collected overnight at 2°C and the first 70

fractions were assayed for calmodulin activity the fol lowing morning.

Fractions

containing calmodulin activity were pooled and concentrated by ultrafiltration
(Amicon, YM5).
Calmodulin was further purified by a preparative PAGE.
(Shandon Southern Instruments,

A 10% gel column

Inc., Sewickley, PA) was prepared with a gel

buffer containing 39 mM NaH2P04, 123 mM Na2HP04, 0.46% TEMED, and 1 mM EGTA
(pH 7.0); electrolyte buffer contained 88 mM NaH2P04, 23 mM Na2HP04, 640 mM
glycine, and 1 mM EGTA (pH 6.0). Partially purified CaM (1.5 ml of Cg astrocytoma
or rat cerebrum post-Sephadex concentrate) containing 0.32 M sucrose was appl ied
to

the

gel.

Electrophoresis was

started

at

25 mA for

the first hour and

maintained at 60 mA thereafter, using a constant current power supply (BioRad Laboratories, Model 500/200, Richmond, CA).

Protein was eluted with 100
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mM TRIS

buffer containing 0.1 mM calcium

ml/minute.

(pH

7.6)

at

a flow rate of 0.3

The entire procedure was carried out in a cold-room and the column

was continuously cooled by passing refrigerated coolant through an outer sleeve
and an inner finger.

Each fraction was collected for twenty minutes, diluted

1:10, and assayed for CaM activity.
pooled

and

concentrated

by

Fractions containing CaM activity were

ultra-filtration

(Amicon

YM-5).

Aliquots

of

concentrated material were stored at -70°C without loss of activity for up to
6 months.
Assay of CaM and effects of CaM antagonists
The activity of calmodulin was determined by its ability to activate a
CaM-sensitive form of cyclic nucleotide phosphodiesterase which was prepared
from mouse cerebrum as previously described (17).

The activity of cyclic AMP

phosphodiesterase was determined by the 1 uciferin-1uciferase method (46).
assay mixture contained 50 mM glycylglycine buffer myokinase

The

(0.25 unit),

pyruvate kinase (0.50 unit), 25 mM ammonium acetate, 3 mM MgC12» 0.1 mM CaCl2,
0.4 mM cyclic AMP, 5 mM dithiothreitol, 0.26 mM phosphoenolpyruvate, 1 nM ATP
(pH

8.0)

and

phosphodiesterase

Concentrations

in

of phosphodiesterase

insure linearity of the assay.

a

total

volume

and time of

of

100

microliters.

incubation were chosen

to

Using our preparations of phosphodiesterase

and CaM, there was at least a 4 fold activation of the enzyme in all experiments.
Quantitation
comparing

of

its

biologically
activation

active CaM
of

in

each

phosphodiesterase

sample was
to

the

determined
activation

by
of

phosphodiesterase by known quantities of a purified preparation of CaM from
bovine brain (Calbiochem, LaJolla, CA).
In these experiments, three to five concentrations of each tissue sample
were assayed for CaM activity to determine the range in which the activity was

10

1 inear with respect to concentration of tissue.

Comparisons between the tissues

were carried out on the same day using freshly prepared tissue in the same assay.
The effect of antagonists on CaM-dependent activity of phosphodiesterase
was measured by the ability of various concentrations of drug to inhibit the
activation of phosphodiesterase in the presence of 2 units of CaM.

One unit

of activity was defined as the amount of calmodulin required to achieve 50%
of the maximum activation of the enzyme.

The effects of CaM antagonists and

their vehicles on the standard curve were determined and corrected as necessary.
Comparisons between the tissues were done in the same assay.
Analytical Electrophoresis
SDS PAGE was performed as described by Laemmli
gel

(47).

A 16% acrylamide

(pH 8.9) was used with sample buffers containing 0.11 M Tris,

sucrose, 0.2% SDS and either 5 mM EGTA or 5 mM calcium chloride

0.11

M

(pH 7.5).

Electrolyte buffer contained 0.43 M glycine, 0.05 M TRIS, 0.1% SDS (pH 8.7).
Proteins were visualized by the use of Coomassie staining.

Molecular weight

standards were obtained from Pharmacia (Piscataway, NJ).
Protein determinations and statistical analysis
Protein concentrations were determined by the method of Lowry (48) and
statistical significance by Student's t-test.
Drugs
Trifluoperazine and chlorpromazine were gifts from Dr. Alfred Brown (Smith
Kline

Beckman,

Philadelphia,

PA):

Fluphenazine

was

a

gift

from

Dr.

Fred

Gorelick; Flunarazine, Melittin and the histones, H^ and H2B were purchased
from Sigma Co. (St. Louis, M0): calmi dazol i urn was kindly provided by Dr. James
Long,

Janssen

Pharmaceutical

Company

(Piscattaway, NJ).

Calmidazoliurn was

dissolved in dimethylsulfoxide; the effect of this vehicle was determined for

11

and subtracted from all parts of the assay.

All other drugs were dissolved

in distilled water.
Miscel1aneous
PMSF,

5'

adenosine-monophosphate,

cyclic AMP,

and

firefly

luciferin-

luciferase were obtained from Sigma Co. (St. Louis, MO); myokinase and pyruvate
kinase were obtained from Boehringer-Mannheim (New York, NY);

bovine brain

calmodulin was obtained from Calbiochem (LaJolla, CA); Spectrapor^ dialysis
tubing with a m.w. cutoff of 3,500 was obtained from Spectrum Medical

Ind.,

Inc. (Los Angeles, CA) and was prepared by boiling in double-distilled water.
The remaining reagents were electrophoretic or reagent grade and were purchased
from commercial sources.
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RESULTS
Concentration of biologically active CaM from

astrocytoma cells and cerebrum

The concentration of biologically active CaM in the supernatant fraction
was similar in C5 astrocytoma cells (26 + 7 ng/mg protein, n = 3) to that of
cerebrum (37 + 14 ng/mg protein, n = 4) (p > 0.5).
Purification of CaM from Cfi astrocytoma and cerebrum
CaM from the acid-heat treated supernatant was further purified by gel
filtration and preparative PAGE.
the gel

filtration column

Both preparations eluted identically from

(data not shown).

This material was pooled and

concentrated to 1.5 ml then applied to the preparative PAGE apparatus.

Figure

1 shows the electrophoretic profiles of CaM emerging from the preparative PAGE.
CaM from both tissues eluted in a single major peak of activity after 4 hours
of electrophoresis in fractions 10 to 30.

The material from each source was

found to be homogeneous under denaturing conditions (Figure 2).
Table 1

shows the results of purification of CaM.

Following acid and

heat precipitation, there was similar CaM present in C5 astrocytoma cells and
rat cerebrum.
from

both

Gel filtration resulted in a 2 fold purification of the molecule

sources

contaminating

but

nucleotides

luciferase assay.

more

importantly

which

otherwise

reduced
interfere

the

concentration

with

the

of

luciferin-

Following preparative PAGE of the concentrated material,

the recovery of CaM varied between experiments but was in the range of 40%70%.

Overall, in several experiments, the recovery of CaM from cerebrum was

greater than the recovery from the C5 cells.
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Characterization of CaM from Cfi astrocytoma and cerebrum
The preparations of purified CaM were further character!'zed according to
their ability to migrate in polyacrylamide gels under denaturing conditions.
Figure 2 demonstrates that the electrophoretic mobility of the CaM prepared
from C5 astrocytoma cells was similar to that prepared from rat cerebrum and
had an apparent m.w. of 15,000.
brain

purchased from

Both migrated identically to CaM from bovine

a commercial

source.

Figure

2

also

shows

that

all

preparations of CaM showed similar shifts in electrophoretic mobility in the
presence of calcium.
Effect of CaM antagonists on CaM purified from C^ astrocytoma cells and rat
cerebrum
Table 3 shows that the effect of CaM antagonists on CaM purified from C5
astrocytoma cells and CaM purified from rat cerebrum was simi 1 ar. Calmidazol i urn
and melittin, were the most potent compounds studied (IC50 values of 10-14 nM
and 12-15 nM respectively).
were slightly less potent

The basic peptides, histone H]_ and histone H2B
Flunarazine,

a piperazine

derivative was more potent than the phenothiazines (IC50 3 pM).

Fluphenazine

and

trifluoperazine

were

(IC50 of

22-36 nM).

intermediate

in

potency

(IC50

5-8

pM

and

9

pM

respectfully) and chiorpromazine was the least potent inhibitor studied (IC50
of 16-20 pM).
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DISCUSSION
These studies demonstrate the feasibility of purifying CaM by preparative
PAGE

and

cerebrum

also

demonstrate the

and

a

malignant

similarities

astrocytoma

between

cell

CaM

line.

purified

The

from rat

concentration

of

biologically active CaM was not significantly different in the two preparations.
This observation confirms earlier work by Brostrom and Wolff (49) who found
similar concentrations and similar biochemical characteristics of CaM in C5
cells

compared

to

that

of

brain.

However,

others

have

found

that

the

concentration of CaM was increased in certain tumors and transformed cell lines
(reviewed in 7,22).

Since cerebrum contains many cell types which conceivably

vary in their concentration of CaM (50), while the C5 line is a malignancy of
astrocytes,

purified

preparations

of

astrocytes

might

be

necessary

to

demonstrate significant differences in concentrations of CaM.
The

CaM

isolated

qualitatively similar.

from

cerebrum

and

C5

astrocytoma

cells

were

also

For example, they had the same estimated m.w. by gel

filtration (data not shown) and by SDS-PAGE (Figure 2); they showed identical
shifts of mobility in the presence of calcium (Figure 2) and; they had similar
sensitivity to inhibition by antagonists (Table 2).
We studied several

different types of CaM antagonists to optimize the

chances of demonstrating pharmacological differences between the CaMs.

For

example, the phenothiazines require calcium-dependent hydrophobic, geometric
and ionic interactions with CaM (51) while the histones may be more dependent
on the ionic properties of the molecules (52).

Flunarazine may be a tissue

selective inhibitor of CaM-stimulated phosphodiesterase

(53).

However,

as

shown in Table 2, we found no significant differences in the sensitivity of
the preparations of CaM to any of the antagonists.

The similar pharmacological

15

properties

of

the

two

CaM's

is

further

evidence

for

their

structural

equivalence.
Recently,

oncomodulin,

a unique calcium-binding protein resembling (3-

parvalbumin has been found exclusively in tumor cells and human placenta (54).
We have not identified this protein in our preparations.

This can be explained

by the recently observed phenomena that unlike CaM, oncomodulin is a far more
potent

activator

of

CaM-sensitive

phosphodiesterase

from

heart

than

of

phosphodiesterase from brain (55,56) and might go undetected in our assay.
This study also demonstrated that preparative PAGE is a rapid and simple
technique for purifying CaM.

This procedure was based on earlier work on the

purification of cyclic nucleotide phosphodiesterase by Uzunov and Weiss (17).
These investigators demonstrated the separation of CaM from phosphodiesterase
using preparative PAGE, but were unable to separate the CaM from other proteins.
To overcome this, we used a higher percentage acrylamide gel (10% vs 7.5%) and
a lower

pH

buffer

system to slow the migration

proportion to the smaller, more acidic CaM molecule.

of other

proteins out of

This resulted in excellent

separation of CaM from contaminating proteins (Table 2 and Figure 2).

Although

the final products appear homogenous on SDS PAGE, the use of two dimensional
electrophoresis and isoelectric focusing or high pressure liquid chromatography
might prove helpful in determining ultimate purity.

The entire procedure takes

less than 48 hours including the initial gel filtration step which removed the
high

concentration

of

nucleotides

present

in

interfere with the 1 uciferin-1uciferase assay.

the malignant

cells

which

Since many investigators assay

CaM by other techniques, it is likely that direct preparative PAGE of the acidheat treated soluble supernatant would give excellent results that could be
completed in one day.
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The 70% yield and approximately 20 fold purification from the already
partially purified soluble supernatant is comparable to standard methodology
(57-59). The overall yield was in the range of 20 mg of CaM per kg of original
tissue.
CaM purified by this technique was authenticated by;
migration

to

that

of

bovine

brain

CaM

in

SDS

gels

1)

its

(Figure

identical

2);

2)

its

characteristic shift in electrophoretic mobility in the presence of calcium
(Figure 2); 3) its ability to activate phosphodiesterase and; 4) its inhibition
by CaM antagonists (Table 2).
The recovery of CaM from Cg cells compared to that from cerebrum was
generally lower after preparative-PAGE.
were

due

to

contaminating

proteases

It seems uni ikely that the differences
because

of

the

presence

concentration of the protease inhibitors PMSF and EGTA.

of

excess

It is also possible

that the CaM of tumor cells remained tightly associated with a CaM-binding
protein and migrated differently during electrophoresis.
of the calcium-chelator, EGTA, during all

Flowever, the presence

steps of the purification should

have allowed for separation of CaM from most of its binding sites.
The pharmacological properties of CaM from a normal
line have not been previously compared.

and malignant cell

The similarities demonstrated in the

present studies may have further implications.

For example, others have shown

that hydrophobic, cationic molecules can inhibit the growth of malignant cells
in vitro (7,21,29-32,34) and in vivo (33) and have correlated this effect with
the potency of the agents as CaM antagonists (30). Furthermore, CaM antagonists
were shown to enhance the cytotoxicity of bleomycin (60,61) and modulate the
resistance of certain cells
results

have

led

chemotherapeutic

to

the

trials

to adriamycin

inclusion
(62).

of

and vincristine

phenothiazines

However,

the

in

inability

(36,37).

These

clinical

cancer

to

demonstrate

17

pharmacological differences between CaM from a normal tissue and a malignant
cell

line raises questions regarding potential

selectivity of drug action.

This does not rule out the possibility that alterations of CaM exist in other
malignant tissues, or that selectivity could be achieved through variations
in uptake or distribution of the drug.

The use of preparative PAGE should

provide a simple technique for comparing the molecule from other normal and
malignant cell lines to determine if exploitable differences might exist.
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LEGENDS TO TABLES

TABLE 1

Purification of CaM from C5 Astrocytoma and rat cerebrum

CaM was prepared from C6 astrocytoma cells and rat cerebrum
as described in Methods.

Fractions under a single peak

of CaM activity (isolated by gel filtration or preparative
PAGE) were obtained, pooled, concentrated, and assayed as
described in methods.

TABLE 2.

Effect of Antagonists

on

the Activity of CaM from C5

Astrocytoma Cells and Rat Cerebrum

CaM and phosphodiesterase were purified as described in
Methods.

The effect of antagonists and their vehicles was

determined in the presence of 2U of CaM.
concentration

of

drugs

fluphenazine

3-100

was;

pM,

The range of

trif1uoperazine
chlorpromazine

1-128
6-100

pM,
pM,

calmidazol i urn 0.001-0.2 pM, melittin 0.001-0.5 pM, histone
HI 0.01-1 pM, histone H2 0.01-1 pM, and flunarazine 1-100
pM.

IC50 was

defined

as

the

concentration

of

agent

necessary to inhibit the activation of phosphodiesterase
by 50%.

Each IC50 value was determined from individual

dose-response curves run in triplicate.

There was less

than a 5% inhibition of phosphodiesterase by drugs when
CaM was omitted from the assay.
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TABLE 2
Effect of Antagonists on CaM Purified from Cg and
rat cerebrum

DRUGS

Rat Cerebrum

C6
iCgn (mM)

Phenothiazines
Trif1uoperazine

8.6

9.2

FIuphenazine

5.0

8.5

16.0

20.0

Chlorpromazine

Peptides
Melittin

0.01

0.02

Hi Histone

0.02

0.03

H2B Histone

0.05

0.04

Calmidazoliurn

0.01

0.01

FIunarazine

2.5

3.3

Other
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LEGENDS TO FIGURES

Figure 1.

Preparative polyacrylamide gel electrophoresis of CaM from C5
astrocytoma cel Is and rat cerebrum. 1-2 mg of protein was appl ied
to the 10% polyacrylamide gel column and collected as described
in

methods.

Broken

line

indicates

the

activity

of

phosphodiesterase in the absence of added CaM.

Figure 2.

SDS-polyacrylamide gel electrophoresis of CaM purified from C5
astrocytoma cells,

rat cerebrum,

and bovine brain.

CaM was

purified from C5 astrocytoma and rat cerebrum by preparative
PAGE as described in Methods.

5 pg of protein was applied to

each lane of the 16% gel in a buffer containing either 5 mM EGTA
(-) or 5 mM CaC12 ( + ).

Molecular weight standards

included

ribonuclease A (13,700), chymotripsinogen A (25,000), ovalbumin
(43,000), and bovine serum albumin (67,000).

Calmodulin-sensitive Phosphodiesterase Activity
(pmoles cyclic AMP hydrolyzed/ml/min)

PREPARATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS
OF CALMODULIN FROM C6 ASTROCYTOMA CELLS
AND RAT CEREBRUM
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20

i

i_i

40
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ELECTROPHORETIC MOBILITY OF
VARIOUS PREPARATIONS OF CALMODULIN
IN 16% SDS- PAGE
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